Verona Pharma Plc Net Income per Employee (VRNA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Verona Pharma Plc  (NASDAQ: VRNA)
 

Verona Pharma Plc Net Income per Employee

VRNA's Quarterly Results, Trends, Rankings, Statistics
Verona Pharma Plc recorded a cumulative net loss of $-81 million during 12 month ending in the second quarter 2025.
The Healthcare sector has seen employees of 258 other companies achieving higher income per employee. While Verona Pharma Plc's total ranking has deteriorated compared to the previous quarter from 1646 to 4012.


What is Income per Employee Ratio?






VRNA Net Income per Employee (Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,027,684 -2,075,228 -2,195,165 -1,945,861 -1,587,949
VRNA's Total Ranking # 4012 # 1646 # 2282 # 2400 # 2691
Seq. Net Income Change - - - - -


VRNA Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 259
Healthcare Sector # 662
Overall Market # 4012

Net Income per Employee Statistics
High Average Low
$ -641,620 $ -1,095,496 $ -2,195,165
(Sep 30 2023)   (Dec 31 2024)







Companies with similar Income per Employee for 12 month ending Jun 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2025Number of Employees Jun 30 2025


Date modified: 2026-07-07T14:08:26+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.